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Abstract Apolipoprotein E (ApoE)-e4 allele has been associated with late onset familial Alzheimer's disease (AD). In both familial and sporadic 
AD brain, ApoE is localized to the vessel walls, senile amyloid plaques, and neurofibrillary tangles. ApoE is also an 'injury-response' macromolecule 
in peripheral nerves and was reported to increase in response to injury. We have demonstrated that Alzheimer fl-amyloid precursor protein and a 
serpin cq-antichymotrypsin also found accumulated in senile plaques in AD brain, were also localized at neuromuscular junctions (NMJs). Using 
immunocytochemistry, our present results indicate that ApoE is found in normal mouse, rat and human skeletal muscle and concentrated at the NMJs 
as it is in the senile plaques in AD brain. Such experiments may shed light on the mechanism of synapse loss, as well as plaque formation in this 
neurodegenerative disease. 
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1. Introduction 
Apolipoprotein E (ApoE) is a 299 amino acid plasma protein 
which has been found in Alzheimer senile plaques, vascular 
amyloid and neurofibrillary tangles [1]. It is encoded by 4 exons 
of a gene located on human chromosome 19 [2]. There are 3 
major isoforms, ApoE2, E3 and E4, each differing from the 
other by only 2 amino-acids [3], encoded by 3 different alleles 
e2, e3 and e4 [4]. The ApoE-g4 allele is reported to correlate 
best with Alzheimer pathology in late-onset familial [5,6] and 
may convey increased risk in the sporadic disease [7]. Dys- 
trophic neurites are an important and a consistent pathological 
finding associated with senile plaques in AD [1]. Synapse loss, 
previously predicted to be the site of dysfunction in AD [8] has 
more recently been correlated with the severity of the symptoms 
and the importance of the dementia s quantified by neuropsy- 
chological testing [9,10]. 
In an effort to understand the mechanisms involved in this 
synaptic alteration, we have utilized the neuromuscular junc- 
tion (NMJ) as a convenient model for cholinergic nicotinic 
synapse studies (see [11]). Originally proposed for synaptic de- 
generation in the pathogenesis of amyotrophic lateral sclerosis 
[12], more recent studies have shown that fl-amyloid protein 
precursor, ~j-antichymotrypsin a d protease nexin I, three 
serine protease inhibitors that accumulate in the brain of AD 
patients, were localized at normal NMJs [13,14]. In addition, 
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the synapse-organizing macromolecule, agrin, contains serine 
protease inhibitor domains (Kazal-type) and is a protease in- 
hibitor [15]. 
Since ApoE has been associated with fl-amyloid peptide in 
AD brain [5], we decided to investigate whether ApoE was also 
present at NMJs junctions of skeletal muscle using immunocy- 
tochemical studies with a polyclonal antibody raised against 
ApoE. We now demonstrate that ApoE is expressed in all 
NMJs of mouse, rat and human skeletal muscle. 
2. Materials and methods 
Biopsy material from the hippocampus ofa familial AD patient was 
used after fixation of the whole brain in 4% neutral-buffered formalin 
for 4 weeks. Tissue blocks were embedded in paraffin. 
Deltoid muscle biopsies were obtained from adult subjects without 
detectable skeletal muscle disease and were frozen without fixation by 
quick immersion in isopentane chilled in liquid nitrogen and stored at 
-80°C until used. Adult BALB/c mice and Wistar rats (Centre d'l~le- 
vage R. Janvier, Le Genest, France), were killed by cervical dislocation, 
and the gastrocnemius muscles removed. These specimens were frozen 
as above. 
2.1. ApoE immunoeytochemistry and acetyleholine receptor visualization 
For immunocytochemistry, 8/.tm transverse cryostat or paraffin sec- 
tions were made and deposited on gelatin-subbed microscope slides. A 
polyclonal antibody made against purified ApoE (Cortex Biochem Inc., 
San Leandro, CA) diluted 1 : 100 in phosphate buffered saline (PBS) 
containing 0.3% Triton X-100 (PBST) and 1% bovine serum albumin 
(BSA) was incubated for 2 h at room temperature. 
Sections were further incubated for one hour in anti-goat biotinyl- 
ated F (ab') 2 fragments of IgG (Amersham, Les Ulis, France) diluted 
1:100 in PBST. They were incubated in fluorescein isothyocyanate 
(F1TC)-tagged streptavidin (Amersham) diluted 1:100 in PBST for 
1 h and lastly with tetramethyl rhodamine-labeled ct-bungarotoxin 
(Molecular Probes) diluted 1 : 1,000 to identify acetycholine receptors 
(AChRs) on NMJs as previously described [14]. Omission of primary 
antibody or replacing primary antibody with non-immune goat serum 
were used as negative controls. Brain tissue from a case of familial AD 
was taken as a positive control and processed for ApoE immunocyto- 
chemistry as above. 
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Fig. 1. (a,b) Immunolocalization of ApoE in AD brain paraffin sections. Note the staining by anti-ApoE antibody of vessel walls (a) and senile plaques 
(b; empty arrow). Magnification × 230. (c,d) Immunolocalization f ApoE (d) in human skeletal muscle cryostat sections at NMJ (arrow) an in the 
endomysial vessel walls. NMJs are identified by tetramethyl-rhodamine a-bungarotoxin (c) n the same section, Magnification × 168.
3. Results 
3.1. Immunocytochemical detection of  ApoE in the brain of  AD 
patients 
ApoE immunolabelling was observed in the vessel walls and 
senile plaques in AD brain tissue (Fig. la,b). 
3.2. Immunocytochemical detection of  ApoE & normal adult 
mouse, rat and human skeletal muscle 
In normal human skeletal muscle, immunocytochemical 
staining with antibody against ApoE showed prominent label- 
ing of all NMJs identified by tetramethylrhodamine-labeled 
~-bungarotoxin (Fig. lc,d). In addition, ApoE was also de- 
tected in endomysial vessel walls. 
In normal mouse (Fig. 2a,b) and rat skeletal muscle (Fig. 
2c,d) a similar immunolabeling was observed. 
4. Discussion 
In the present study, we present evidence, for the first time 
to our knowledge, that ApoE is present in mouse, rat and 
human skeletal muscle where it is found in endomysial vessel 
walls and highly concentrated at the NMJ. ApoE at the NMJ 
may originate from the motoneuron and be transported within 
axons. ApoE expression in normal nerve has been interpreted 
to indicate its important role in myelinogenesis where it might 
mobilize lipids into or within the myelin [16]. It may also be, 
that, like protease nexin I [13], ApoE is synthesized in muscle, 
Schwann cells and/or, possibly, macrophages [17] and endothe- 
lial cells. Apo E has previously been detected in non-myeli- 
nating Schwann cells [18]. It is equally possible that NMJ- 
associated ApoE arises from Schwann cells, from the nerve or 
the muscle cell. Precisely where at he synapse, pre- or post- 
synaptic membrane or basement membrane, ApoE is located 
will require ultrastructural nalysis. 
The presence of ApoE at NMJs might arise through its inter- 
action with the ~2-macroglobulin receptor/low density lipopro- 
tein receptor-like protein (a2macR/lrp) which serves to bind 
a2-macroglobulin, a potent protease inhibitor [19], and elastase 
(a serine protease) complex. Other serine protease:serpin com- 
plexes, such as urokinase and plasminogen activator inhibitor-1 
(PAl-l) complexes, also bind to the a2macR/lrp [20]. In this 
respect, we have shown that other protease inhibitors uch as 
protease nexin I, protease nexin II, and a~-antichymotrypsin, 
are present at the NMJ [13,14]. These serine protease inhibitors 
are also concentrated atsenile amyloid plaques in the brain of 
AD patients, like ApoE. Protease nexin II is identical to the 
secreted forms of the fl-amytoid protein precursor, a potent 
inhibitor of chymotrypsin and the coagulation factors XIa and 
IXa [21], and the principal component of senile plaques. ApoE 
is also know to bind to fl-amyloid peptide, although its precise 
interaction isunclear [5]. ApoE, which is also a heparin binding 
protein [22], could promote cell-matrix interactions and stimu- 
late axon extension. It has also a role in membrane lipid biosyn- 
thesis of all cells, not only nerve, and there is evidence that 
Schwann cells, like cortical astrocytes [18,23] or the peripheral 
nerve macrophages during Wallerian degeneration [17,24] pro- 
duce increased amounts of ApoE. 
Our present findings support previous tudies which suggest 
that inhibitors of serine proteases are involved in synaptic sta- 
bilization [12,25,26]. The synapse has been considered an im- 
portant site underlying mechanisms of degeneration i  AD for 
248 M. Akaaboune t al./FEBS Letters 351 (1994) 246~48 
Fig. 2. Immunolocalization of ApoE in gastrocnemius muscle of normal mouse (b) and rat skeletal muscle (d). NMJs (arrow) are identified by 
tetramethyl-rhodamine ~-bungarotoxin (a and c). Magnification × 168. 
more than 20 years (see [8]). Recent evidence has supported and 
extended this supposition [9,10] and shown that synapse loss 
correlates better with dementia than does deposition of either 
amyloid plaques or presence of neurofibrillary tangles. Since 
ApoE is present within senile plaques in AD brains and at 
normal peripheral, cholinergic synapses, tudies in muscle may 
further help our understanding of the mechanism of synapse 
loss, as well as plaque deposition, in this disease. 
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